Physician profile
John C Luce
NPI 1376830596
$2,535.95
in general payments reported to CMS, 2019-2025
28 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Pediatric Rehabilitation Medicine provider received nationally (typical 2025 total: $109).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $224 · 2021: $491 · 2022: $484 · 2023: $260 · 2024: $17.16 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $720.40 | 2019-2025 | Dysport |
| Medtronic, INC. | $176.49 | 2021-2022 | |
| Ucb, INC. | $173.54 | 2019-2023 | Fintepla, Briviact |
| Novartis Pharmaceuticals Corporation | $154.09 | 2019-2021 | |
| Greenwich Biosciences, INC. | $139.14 | 2019-2021 | |
| Hydrofera LLC | $125.17 | 2025 | Sorbact Other |
| Aquestive Therapeutics, INC. | $99.85 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $99.84 | 2022 | |
| Zogenix INC. | $77.64 | 2020-2021 | |
| Ptc Therapeutics, INC. | $71.34 | 2019-2021 | |
| Allergan, INC. | $66.21 | 2020-2021 | |
| Genzyme Corporation | $64.86 | 2019 | |
| Biogen, INC. | $59.42 | 2019-2022 | |
| Immedica Pharma US, INC. | $59.06 | 2022-2023 | |
| Eisai INC. | $58.24 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ns Pharma, INC. | $54.00 | 2021-2022 | |
| Dentsply Ih INC. | $52.14 | 2021 | |
| Sarepta Therapeutics, INC. | $49.60 | 2019-2022 | |
| Piramal Critical Care | $40.79 | 2019-2020 | |
| Abbvie INC. | $32.53 | 2025 | |
| Mallinckrodt Enterprises LLC | $31.24 | 2019 | |
| Neurelis, INC. | $28.21 | 2021 | |
| Acadia Pharmaceuticals INC | $21.80 | 2023 | Daybue |
| Ultragenyx Pharmaceutical INC. | $21.00 | 2022 | |
| Medtronic USA, INC. | $18.56 | 2019 | |
| Cranial Technologies, INC | $17.27 | 2020 | |
| Ironshore Pharmaceuticals INC. | $11.77 | 2019 | |
| Coloplast Corp | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Luce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.